Source MS Trust: NICE has recommended Extavia, but rejected Copaxone, Avonex, Betaferon, Plegridy and Rebif in its preliminary appraisal of MS drugs. The MS Trust has responded to NICE’s consultation in the strongest possible terms. On 20 December 2017 NICE published(link is external) its preliminary decision on the use of Copaxone and the five beta interferon drugs (Avonex, Betaferon, Extavia, Plegridy and Rebif) by… Read more »
Posts Categorized: MS News
Be kind to your mind
Source MS Trust: We often focus solely on our physical health but looking after our mental health is also vital to our sense of wellbeing. Jo Johnson, a consultant neuropsychologist with a special interest in MS, introduces practical steps you can take to improve and maintain your mental wellbeing. “Most of us spend a lot… Read more »
Ocrelizumab licensed for people with early primary progressive MS in the UK
Source MS Society: Ocrelizumab has been approved as the first licensed treatment for some people with primary progressive MS in the UK. Recently recommended by the European Medicines Agency (EMA), today the European Commission approved the licence. UK regulators will now decide whether ocrelizumab should be available on the NHS. Who can get ocrelizumab? The conditions of the licence mean ocrelizumab (brand… Read more »
European Commission Approves Ocrevus to Treat RRMS, PPMS Throughout EU
European Commission Approves Ocrevus to Treat RRMS, PPMS Throughout EU
MS-UK Telephone Counselling Service
MS-UK Telephone Counselling Service MS-UK Counselling was established following consultation with people who had multiple sclerosis (MS), who said that a counselling service would be their choice as a new service. Conversations with clients have already shown that they do not want to feel a burden to their friends or families by talking to them… Read more »
UTI article
Source Miranda’s MS Blog: Miranda is an MS Specialist Nurse based in Bedford, she writes a blog to share things she has found good, useful or positive within the MS community. UTI’s can be a common issue for many people with MS, this interesting article can help you to stay one step ahead. Read on.
Cannabinoid, Dronabinol, Seen as Long-term Treatment Option for Neuropathic Pain in Phase 3 Study
Source Multiple Sclerosis News Today: Multiple sclerosis (MS) patients being treated with dronabinol, a cannabinoid, do not show signs of drug abuse or dependency, leading researchers to conclude it has potential to be a long-term and safe treatment option for neuropathic pain. The issue of pain management, specifically central neuropathic pain (CNP), in patients with autoimmune disorders… Read more »
Ozanimod Superior to Avonex in Treating Relapsing MS in Phase 3 Trials, Celgene Reports
Source Multiple Sclerosis News Today: Celgene released the results of two Phase 3 trials showing that patients with relapsing multiple sclerosis (MS) who were treated with ozanimod had lower relapse rates and fewer MRI brain lesions compared to those given a current first-line therapy, Avonex (interferon β-1a). These results will be used to support a request for ozanimod’s approval as an MS… Read more »
The MS Society explore 5 myths about cannabis and MS
Source MS Society: There’s mounting evidence to show that cannabis could help pain and muscle spasms for people with MS. But with tonnes of information swirling around the internet, it’s hard to be sure what’s true and what’s not. We dived into the details to bust 5 common myths about cannabis and MS: 1. ‘Cannabis for… Read more »
Diagnostic Blood Test May Be Able to Distinguish Between RRMS and PPMS, Researchers Say
Source Mutiple Sclerosis News Today: In the future, a blood test may make diagnosing multiple sclerosis (MS) much easier, thanks to newly identified biomarker patterns that distinguish between MS patients and healthy people. The test could also correctly detect primary progressive MS (PPMS) in patients who also had relapsing-remitting disease (RRMS). Australian researchers suggest that… Read more »
